Elan dumps MS candidate and revels in EDT decision
This article was originally published in Scrip
Executive Summary
Irish drug-maker Elan has made a "business portfolio decision" to discontinue development of ELND002 in multiple sclerosis (MS). Elan made the announcement during its fourth quarter and full year 2011 results, where it revealed that excluding the recently divested Elan Drug Technology (EDT) business, revenues were up by 19% over full-year 2010 to $1.07 billion.